InMed Pharmaceuticals’ (INM) Sell (E+) Rating Reaffirmed at Weiss Ratings

InMed Pharmaceuticals (NASDAQ:INM)‘s stock had its “sell (e+)” rating restated by investment analysts at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

Separately, Wall Street Zen upgraded shares of InMed Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, July 18th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

InMed Pharmaceuticals Trading Up 8.8%

NASDAQ INM opened at $2.46 on Wednesday. The company has a market capitalization of $5.85 million, a PE ratio of -0.20 and a beta of 0.30. The company has a fifty day moving average of $2.25 and a 200 day moving average of $2.57. InMed Pharmaceuticals has a 1 year low of $1.72 and a 1 year high of $8.27. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.99 and a quick ratio of 6.47.

About InMed Pharmaceuticals

InMed Pharmaceuticals Inc, a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry.